ETF Holdings Breakdown of CYTK

News associated with CYTK

Cytokinetics (NASDAQ:CYTK) Reaches New 52-Week Low on Analyst Downgrade

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) hit a new 52-week low during trading on Wednesday after Barclays lowered their price target on the stock from $55.00 to $53.00. Barclays currently has an overweight rating on the stock. Cytokinetics traded as low as $32.30 and last traded at $33.41, with a volume of 854150 shares […] - 2025-05-09 05:40:52

Envestnet Asset Management Inc. Reduces Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)

Envestnet Asset Management Inc. trimmed its stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 20.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,455 shares of the biopharmaceutical company’s stock after selling 6,612 shares during the quarter. Envestnet […] - 2025-05-01 07:36:51

Guggenheim Capital LLC Sells 4,898 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Guggenheim Capital LLC decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 12.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 35,988 shares of the biopharmaceutical company’s stock after selling 4,898 shares during the period. Guggenheim Capital LLC’s holdings in Cytokinetics were worth $1,693,000 as of its most recent […] - 2025-04-21 08:18:53

Bank of America Has Lowered Expectations for Cytokinetics (NASDAQ:CYTK) Stock Price

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price objective reduced by Bank of America from $62.00 to $54.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Bank of America‘s price target indicates a potential upside of 37.93% from the stock’s […] - 2025-04-17 07:48:49

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $82.00 Average Target Price from Analysts

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have earned an average rating of “Moderate Buy” from the eighteen analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, fifteen have issued a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-04-15 05:46:42

California Public Employees Retirement System Sells 48,263 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 26.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 135,473 shares of the biopharmaceutical company’s stock after selling 48,263 shares during the period. California Public Employees Retirement […] - 2025-04-08 08:51:09

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $17,743.50 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) Director Robert Arthur Harrington sold 450 shares of the company’s stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $39.43, for a total value of $17,743.50. Following the transaction, the director now directly owns 14,658 shares of the […] - 2025-04-08 08:14:51

Franklin Resources Inc. Has $25.68 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

Franklin Resources Inc. boosted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The firm owned 545,813 shares of the biopharmaceutical company’s stock after purchasing an additional 9,366 shares during the quarter. Franklin Resources Inc.’s holdings in Cytokinetics were worth $25,675,000 as of its most […] - 2025-04-07 09:11:06

Prudential Financial Inc. Cuts Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Prudential Financial Inc. lowered its stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 16.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 25,336 shares of the biopharmaceutical company’s stock after selling 5,157 shares during the quarter. Prudential Financial Inc.’s holdings in Cytokinetics were worth $1,192,000 […] - 2025-04-07 07:41:04

Sei Investments Co. Sells 1,472 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Sei Investments Co. decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.6% during the fourth quarter, HoldingsChannel reports. The firm owned 89,560 shares of the biopharmaceutical company’s stock after selling 1,472 shares during the period. Sei Investments Co.’s holdings in Cytokinetics were worth $4,213,000 as of its most recent SEC […] - 2025-04-03 08:26:48

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,915,821 shares of the biopharmaceutical company’s stock after purchasing an additional 154,216 shares during the […] - 2025-04-01 10:16:45

Analyzing Cytokinetics (NASDAQ:CYTK) and Portage Biotech (NASDAQ:PRTG)

Portage Biotech (NASDAQ:PRTG – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends. Volatility and Risk Portage Biotech has a beta of […] - 2025-04-01 05:57:32

Cytokinetics (NASDAQ:CYTK) and GT Biopharma (NASDAQ:GTBP) Head-To-Head Analysis

GT Biopharma (NASDAQ:GTBP – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Volatility and Risk GT Biopharma has a beta of […] - 2025-03-28 05:34:46

Natixis Advisors LLC Sells 3,936 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Natixis Advisors LLC lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 10.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,659 shares of the biopharmaceutical company’s stock after selling 3,936 shares during the period. Natixis Advisors LLC’s holdings […] - 2025-03-25 08:30:51

Brokerages Set Cytokinetics, Incorporated (NASDAQ:CYTK) Price Target at $82.00

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eighteen research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, fifteen have issued a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-03-21 05:34:50

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Arizona State Retirement System

Arizona State Retirement System raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 32,366 shares of the biopharmaceutical company’s stock after buying an additional 600 shares during the period. Arizona […] - 2025-03-13 09:30:51

Handelsbanken Fonder AB Grows Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Handelsbanken Fonder AB raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 9.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,300 shares of the biopharmaceutical company’s stock after acquiring an additional 2,900 shares during the quarter. […] - 2025-02-27 08:58:55

Mirae Asset Global Investments Co. Ltd. Sells 323 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Mirae Asset Global Investments Co. Ltd. lessened its stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,933 shares of the biopharmaceutical company’s stock after selling 323 shares during the period. Mirae Asset Global […] - 2025-02-14 08:32:54

abrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

abrdn plc grew its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 29.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 450,513 shares of the biopharmaceutical company’s stock after purchasing an additional 102,457 shares during the period. abrdn plc owned approximately 0.38% of Cytokinetics […] - 2025-02-07 09:28:52

CYTK institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	71,018	USD 2,306,665
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	60,916	USD 1,978,552 -1.7%
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	56,380	USD 1,831,222
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	56,380	USD 1,831,222 -1.7%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,454	USD 47,226
Total =		246,148	USD 7,994,887

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer